METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE
Presented herein are methods for treatment or prevention of opioid induced constipation by administration of oral compositions of methylnaltrexone. The methods are based, at least in part, on the identification of subjects that are particularly susceptible to such treatment and optimal dosages of such oral compositions to treat or prevent opioid induced constipation and, further, to minimize the occurrence of adverse events associated with such treatment.
1 . A method of treating a subject having opioid induced constipation, comprising orally administering to the subject a pharmaceutical composition comprising a salt of formula (I):
wherein A − is an anion of an amphiphilic pharmaceutically acceptable excipient, wherein the administration of the pharmaceutical composition results in a rescue free bowel movement;
thereby treating the subject.
2 . (canceled)
3 . The method of claim 1 , wherein A − is sodium dodecyl (lauryl) sulfate.
4 . The method of claim 1 , wherein the pharmaceutical composition comprises a combination of a first salt comprising methylnaltrexone and bromide, and a second salt comprising methylnaltrexone and sodium dodecyl (lauryl) sulfate.
5 . (canceled)
6 . The method of claim 1 , wherein the pharmaceutical composition further comprises at least one agent selected from the group consisting of sodium bicarbonate, microcrystalline cellulose, crospovidone, polysorbate 80, edetate calcium disodium dehydrate, silicified microcrystalline cellulose, talc, colloidal silicon dioxide, magnesium stearate, and combinations thereof.
7 . The method of claim 1 , wherein the pharmaceutical composition is a tablet.
8 . The method of claim 1 , comprising orally administering about 150 mg, 300 mg or 450 mg of methylnaltrexone, or a salt thereof.
9 . The method of claim 8 , wherein the about 150 mg of methylnaltrexone is administered as one tablet comprising about 150 mg of methylnaltrexone, the about 300 mg of methylnaltrexone is administered as two tablets each comprising about 150 mg of methylnaltrexone, or the about 450 mg of methylnaltrexone is administered as three tablets each comprising about 150 mg of methylnaltrexone.
10 - 13 . (canceled)
14 . The method of claim 1 , wherein the subject has chronic non-malignant pain, optionally for at least 2 months prior to administration of the pharmaceutical composition.
15 . (canceled)
16 . The method of claim 1 , wherein the subject has been receiving opioid treatment prior to administration of the pharmaceutical composition, optionally for at least one month.
17 . (canceled)
18 . The method of claim 1 , wherein the subject has been receiving opioid treatment comprising at least 50 mg of oral morphine equivalents per day for at least 14 days.
19 . (canceled)
20 . The method of claim 1 , wherein the subject has had opioid induced constipation for at least 30 days.
21 . The method of claim 1 , wherein the subject has experienced less than 3 rescue free bowel movements per week for at least four consecutive weeks, straining during bowel movements, incomplete evacuation, or a Bristol Stool Form Scale type 1 or 2 for at least 25% of rescue free bowel movements.
22 - 24 . (canceled)
25 . The method of claim 1 , wherein the method results in (i) a rescue free bowel movement within 4 hours of administration of the pharmaceutical composition; (ii) an increase of at least one, two, three, four or five rescue free bowel movements per week as compared to the number of rescue free bowel movements per week prior to administration of the pharmaceutical composition; or (iii) an increase of at least one rescue free bowel movement per week for each of the first 4 weeks of daily administration of the pharmaceutical composition.
26 - 28 . (canceled)
29 . The method of claim 1 , wherein (i) the subject experiences at least 3 rescue free bowel movements in each of the first 4 weeks of daily administration of the pharmaceutical composition; and (ii) the subject experiences an increase of at least one rescue free bowel movement per week for at least 3 of the first 4 weeks of daily administration as compared to the number of rescue free bowel movements per week prior to administration of the pharmaceutical composition.
30 - 31 . (canceled)
32 . A method of increasing the number of rescue free bowel movements experienced by a subject, comprising orally administering to the subject a pharmaceutical composition comprising a salt of formula (I):
wherein A − is an anion of an amphiphilic pharmaceutically acceptable excipient, thereby increasing the number of rescue free bowel movements experienced by the subject.
33 . The method of claim 32 , wherein the subject is administered the pharmaceutical composition at least once a day for at least four weeks.
34 . The method of claim 33 , wherein the subject experiences an increase of at least one rescue free bowel movement for at least 3 out of the four weeks and wherein the subject experiences at least 3 rescue free bowel movements for each of the four weeks.
35 . The method of claim 32 , wherein the number of rescue free bowel movements increases each of the four weeks as compared to the number of rescue free bowel movements experienced by the subject prior to administration.
36 . A method of assessing the efficacy of the pharmaceutical composition of claim 1 in treating a subject suffering from opioid induced constipation, comprising orally administering to the subject a pharmaceutical composition comprising a salt of formula (I):
wherein A − is an anion of an amphiphilic pharmaceutically acceptable excipient, wherein at least one of:
(i) a rescue free bowel movement within four hours of administration of the pharmaceutical composition;
(ii) an increase in the number of rescue free bowel movements per week upon daily administration of the pharmaceutical composition as compared to the number of rescue free bowel movements per week prior to daily administration of the pharmaceutical composition; or
(iii) an increase in the number of rescue free bowel movements per week upon daily administration of the pharmaceutical composition as compared to the number of rescue free bowel movements per week prior to administration of the pharmaceutical composition in at least three of the first four weeks of daily administration; and at least three rescue free bowel movements per week for the first four weeks of daily administration;
is indicative of the efficacy of the pharmaceutical composition.
37 . The method of claim 1 , further comprising identifying if the subject:
(i) has chronic non-malignant pain;
(ii) has had chronic non-malignant pain for at least 2 months;
(iii) has been receiving opioid treatment;
(iv) has been receiving opioid treatment for at least one month;
(v) has been receiving opioid treatment comprising at least 50 mg of oral morphine equivalents per day for at least 14 days;
(vi) has opioid induced constipation;
(vii) has had opioid induced constipation for at least 30 days;
(viii) has had less than 3 rescue free bowel movements per week for at least four consecutive weeks;
(ix) has experienced straining during bowel movements;
(x) has experienced incomplete evacuation;
(xi) has experienced a Bristol Stool Form Scale type 1 or 2 for at least 25% of rescue free bowel movements;
(xii) has no history of chronic constipation prior to initiation of opioid therapy; or
(xiii) any combination of (i)-(xii); and
orally administering to the subject a pharmaceutical composition comprising a salt of formula (I):
wherein A − is an anion of an amphiphilic pharmaceutically acceptable excipient, wherein the subject exhibits any one of (i)-(x).
38 . A method of reducing the occurrence of adverse events associated with treatment of opioid induced constipation, comprising orally administering to the subject a pharmaceutical composition comprising a salt of formula (I):
wherein A − is an anion of an amphiphilic pharmaceutically acceptable excipient, wherein the pharmaceutical composition reduces the occurrence of adverse events as compared to a pharmaceutical composition not comprising an anion of amphiphilic pharmaceutically acceptable excipient.
39 - 49 . (canceled)
50 . The method of claim 1 , comprising the steps of
(a) orally administering to the subject the pharmaceutical composition comprising about 150 mg of methylnaltrexone, or a salt thereof, and sodium dodecyl (lauryl) sulfate;
(b) determining whether the composition treats the subject, wherein at least one response selected from the group consisting of (i)-(iii) indicates that the composition treats the subject:
(i) a rescue free bowel movement within four hours of administration of the pharmaceutical composition;
(ii) an increase in the number of rescue free bowel movements per week upon daily administration of the pharmaceutical composition as compared to the number of rescue free bowel movements per week prior to daily administration of the pharmaceutical composition; or
(iii) an increase in the number of rescue free bowel movements per week upon daily administration of the pharmaceutical composition as compared to the number of rescue free bowel movements per week prior to administration of the pharmaceutical composition in at least three of the first four weeks of daily administration; and at least three rescue free bowel movements per week for the first four weeks of daily administration;
(c) orally administering a pharmaceutical composition comprising 300 mg or 450 mg of methylnaltrexone, or a salt thereof, and sodium dodecyl (lauryl) sulfate, if the subject does not exhibit a response selected from the group consisting of (b)(i)-(iii) following step (a).
51 . The method of claim 1 ,
wherein the composition provides a dose in the range of about 300 mg to about 400 mg of methylnaltrexone or salt thereof; wherein (i) the method results in a rescue free bowel movement within 4 hours of administration of the pharmaceutical composition; and (ii) the result is sustainable for at least 4 weeks with daily administration.
52 . The method according to claim 51 , wherein the method further provides the subject (i) at least 3 rescue free bowel movements per week for at least 3 of 4 weeks of daily administration of the pharmaceutical composition; and (ii) the subject experiences an increase of at least one rescue free bowel movement per week as compared to the number of rescue free bowel movements per week prior to administration of the pharmaceutical composition.
53 . A method of increasing the bioavailability of MNTX and its metabolites in a subject comprising administering MNTX to a subject orally.
54 - 62 . (canceled)
63 . A method of increasing the bioavailability of MNTX, comprising administering MNTX without food to a subject in need thereof.
64 - 74 . (canceled)
75 . A method of increasing the laxation effect of MNTX, comprising administering MNTX without food to a subject in need thereof.
76 - 81 . (canceled)